BL5923

CAS No. 921208-19-7

BL5923( BL 5923 | BL-5923 )

Catalog No. M16605 CAS No. 921208-19-7

BL5923 (BL-5923) is a potent, highly specific, orally available inhibitor of CCR1 with IC50 of 20.4 and 22.8 nM for human and mouse CCR1, resepctively.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    BL5923
  • Note
    Research use only, not for human use.
  • Brief Description
    BL5923 (BL-5923) is a potent, highly specific, orally available inhibitor of CCR1 with IC50 of 20.4 and 22.8 nM for human and mouse CCR1, resepctively.
  • Description
    BL5923 (BL-5923) is a potent, highly specific, orally available inhibitor of CCR1 with IC50 of 20.4 and 22.8 nM for human and mouse CCR1, resepctively; displays excellent selectivity against a panel of additional chemokine receptors including human CCR2, CCR4, CCR5, CCR6, CCR7, CXCR1, CXCR2, and CXCR3; suppresses colon cancer liver metastasis by blocking accumulation of immature myeloid cells in a mouse mode; ameliorates the progression of lupus nephritis in NZB/W mice; also improves survival, decreases the kidney fungal burden and protects from renal tissue injury in Candida-infected mice.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    BL 5923 | BL-5923
  • Pathway
    GPCR/G Protein
  • Target
    Chemokine Receptor
  • Recptor
    Chemokine Receptor
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    921208-19-7
  • Formula Weight
    487.956
  • Molecular Formula
    C25H27ClFN3O4
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    CC(=O)NC1=CC(=C(C=C1C=CC(=O)N2CC3COCC(C2)N3CC4=CC=C(C=C4)F)OC)Cl
  • Chemical Name
    (E)-N-(5-chloro-2-(3-(9-(4-fluorobenzyl)-3-oxa-7,9-diazabicyclo[3.3.1]nonan-7-yl)-3-oxoprop-1-en-1-yl)-4-methoxyphenyl)acetamide

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Kitamura T, et al. Proc Natl Acad Sci U S A. 2010 Jul 20;107(29):13063-8. 2. Revesz L, et al. Bridged piperazines and piperidines as CCR1 antagonists with oral activity in models of arthritis and multiple sclerosis. Lett Drug Des Discov. 2006;3:689–694. 3. Bignon A, et al. J Immunol. 2014 Feb 1;192(3):886-96. 4. Lionakis MS, et al. Antimicrob Agents Chemother. 2017 Feb 23;61(3). pii: e02365-16.
molnova catalog
related products
  • CXCR2-IN-1

    A potent, CNS penetrant CXCR2 antagonist with pIC50 of 9.3; shows neutrophil chemotaxis inhibition with pIC50 of 7.6.

  • BMS-22

    A potent, selective, allosteric CCR2 antagonist with binding IC50 of 5.1 nM.

  • INCB9471

    A potent, selective and orally bioavailable CCR5 antagonist IC50 of 6.5 nM, Kd of 3.1 nM in human PBMCs.